In the first four-plus months of 2004, there have been two medical device IPOs, compared to zero last year. Yet while a couple of companies does not a trend make, nevertheless, five more device hopefuls in the queue are cautiously optimistic that public investors are beginning to back at least certain kinds of medical device companies. But which kinds? Cutera Inc. raised $45.6 million in its IPO the last day of March [W#200430257]. You could say that the company has made a strong start in an enormous, underpenetrated device market, and one that doesn't suffer from reimbursement risk-the consumer market for cosmetic procedures. But Cutera isn't just a story stock; it's a company with a record of predictably ramping up sales and earnings.
In the first four-plus months of 2004, there have been two
medical device IPOs. Yet while a couple of companies does not a
trend make, nevertheless, five more device hopefuls in the queue
are cautiously optimistic that public investors are beginning to
back at least certain kinds of medical device companies. But which
kinds?
Take Cutera Inc. , which raised $45.6 million in its IPO the last day of March [See Deal]....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
